These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31582326)

  • 1. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma.
    Singal AK; Satapathy SK; Reau N; Wong R; Kuo YF
    Dig Liver Dis; 2020 Jan; 52(1):98-101. PubMed ID: 31582326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
    Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
    Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.
    Noureddin M; Vipani A; Bresee C; Todo T; Kim IK; Alkhouri N; Setiawan VW; Tran T; Ayoub WS; Lu SC; Klein AS; Sundaram V; Nissen NN
    Am J Gastroenterol; 2018 Nov; 113(11):1649-1659. PubMed ID: 29880964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Flemming JA; Kim WR; Brosgart CL; Terrault NA
    Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
    Young K; Liu B; Bhuket T; Gish RG; Wong RJ
    J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Holzner ML; Florman S; Schwartz ME; Tabrizian P
    HPB (Oxford); 2022 Apr; 24(4):470-477. PubMed ID: 34544629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of racial/ethnic and etiology/disease-specific factors is associated with lower survival following liver transplantation in African Americans: an analysis from UNOS/OPTN database.
    Wong RJ; Ahmed A
    Clin Transplant; 2014 Jul; 28(7):755-61. PubMed ID: 24750171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
    Goldberg D; Ditah IC; Saeian K; Lalehzari M; Aronsohn A; Gorospe EC; Charlton M
    Gastroenterology; 2017 Apr; 152(5):1090-1099.e1. PubMed ID: 28088461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Kwong AJ; Kim WR; Flemming JA
    Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in liver transplantation for hepatitis C in a country with reduced access to direct-acting antiviral agents.
    Dirchwolf M; Marciano S; Giunta DH; Posadas-Martínez ML; Biggins SW; Ruf AE
    Clin Transplant; 2018 Apr; 32(4):e13230. PubMed ID: 29485711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965.
    Shirazi F; Wang J; Wong RJ
    J Clin Exp Hepatol; 2020; 10(1):30-36. PubMed ID: 32025164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades.
    Puigvehí M; Hashim D; Haber PK; Dinani A; Schiano TD; Asgharpour A; Kushner T; Kakked G; Tabrizian P; Schwartz M; Gurakar A; Dieterich D; Boffetta P; Friedman SL; Llovet JM; Saberi B
    Am J Transplant; 2020 Jan; 20(1):220-230. PubMed ID: 31437349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
    Vaziri A; Gimson A; Agarwal K; Aldersley M; Bathgate A; MacDonald D; McPherson S; Mutimer D; Gelson W
    J Viral Hepat; 2019 Feb; 26(2):231-235. PubMed ID: 30339294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
    Taniguchi M
    Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
    Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
    Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA.
    Cholankeril G; Goli K; Rana A; Hernaez R; Podboy A; Jalal P; Da BL; Satapathy SK; Kim D; Ahmed A; Goss J; Kanwal F
    Hepatology; 2021 Dec; 74(6):3316-3329. PubMed ID: 34310738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.